Evaluering af sikkerheden og effektiviteten af sent-debuterende Pompes sygdom genterapi
Et multicentreret, enkeltarms, åbent mærket, undersøgelse for at evaluere sikkerheden, tolerabiliteten og effektiviteten af en adenoassocieret virusvektor, der udtrykker den humane syre alfa-glucosidase (GAA) transgen intravenøs injektion hos patienter med sent opstået Pompe-sygdom
This study is being conducted to evaluate the safety and effectiveness of GC301 adeno-associated virus vector expressing codon-optimized human acid alpha-glucosidase (GAA) as potential gene therapy for Pompe disease. Patients diagnosed with late-onset Pompe disease (LOPD) who are ≥ 6 years old will be studied.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: GeneCradle, Inc China
- Telefonnummer: 86-13501380583
- E-mail: ind@bj-genecradle.com
Studiesteder
-
-
-
Beijing, Kina, 100853
- Rekruttering
- Chinese PLA General Hospital
-
Ledende efterforsker:
- Guang Yang
-
Kontakt:
- Xinting Liu
- Telefonnummer: 16601558283
- E-mail: lxting0531@163.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥ 6 years, males or females;
- Patient has a diagnosis of LOPD;
- Patient has upright FVC ≥ 30% of predicted normal value;
- A 6MWT ≥ 40 meters, assistive device allowed;
- The patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed.
Exclusion Criteria:
- Patient who has any history or concurrent clinical organic disease, including cardiovascular and liver diseases, respiratory system, nervous system disease, or any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.
- Patient who requires invasive mechanical ventilation, or rely on noninvasive non-non-invasive assisted ventilation when sitting upright;
- Patient who is positive for human immunodeficiency (HIV) antibody, hepatitis B surface antigen, hepatitis C antibody, or treponema pallidum antibody;
- Patient with a history of glucocorticoid allergy;
- Patient who has a contraindication to study drug or to corticosteroids, or has demonstrated hypersensitivity to any of the components of the study drug;
- Patient who has AAV9 neutralizing antibody titer ≥ 1:100;
- Patient who has participated in a previous gene therapy research trial;
- Pregnant or lactating female participants;
- Patients who have fertility plans within 6 months from screening to the end of the study and are unwilling to take effective physical contraceptive measures (such as a condom, intrauterine device, contraceptive ring, ligation, abstinence, etc.) for contraception (including the subject's partner);
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Low dosage group
Single intravenous administration of GC301 at a dose of 3.0 x 10^13 vector genomes per kilogram body weight |
GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene |
|
Eksperimentel: High dosage group
Single intravenous administration of GC301 at a dose of 6.0 x 10^13 vector genomes per kilogram body weight |
GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Rate for dosisbegrænsende toksicitet (DLT) baseret på protokolspecifikke bivirkninger (fase 1)
Tidsramme: inden for 30 dage efter behandlingen
|
inden for 30 dage efter behandlingen
|
|
|
Number of Participants With Adverse Events
Tidsramme: 52 weeks
|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability |
52 weeks
|
|
Percent Predicted Upright Forced Vital Capacity (FVC)(Phase 2)
Tidsramme: 52 weeks
|
Change from baseline in percentage of predicted FVC measured by pulmonary function testing |
52 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Forekomst af immunrespons mod AAV-capsid og GAA-transgen
Tidsramme: 52 uger
|
52 uger
|
|
|
6-Minute Walk Test
Tidsramme: 52 weeks
|
Change from baseline in the distance walked in the 6 minute walk test (6MWT), which is a standardized assessment of how far an individual can walk on a hard, flat surface in a period of 6 minutes |
52 weeks
|
|
Maximum Inspiratory Pressure (MIP)
Tidsramme: 52 weeks
|
Change from baseline in MIP measured by pulmonary function testing |
52 weeks
|
|
Maximum Expiratory Pressure (MEP)
Tidsramme: 52 weeks
|
Change from baseline in MEP measured by pulmonary function testing |
52 weeks
|
|
Muscle Status Testing - Quick Motor Function Test (QMFT) Measure
Tidsramme: 52 weeks
|
Measurement of functional motor abilities using the Quick Motor Function Test (QMFT) will be performed and the results compared with baseline. |
52 weeks
|
|
Quality of life evaluation: 12-item short form health survey (SF-12) for LOPD participants
Tidsramme: 52 weeks
|
SF-12, a 12 item-questionnaire, used to assess health-related quality of life in participants aged >=18 years at screening/baseline. SF-12 consisted of 12 items, which were categorized into eight domains (subscales) of functioning and well-being: physical functioning, role-physical, role emotional, mental health, bodily pain, general health, vitality and social functioning, with each domain score ranged from 0 (poor health) to 100 (better health), higher scores indicated good health condition. These eight domains were further summarized into 2 summary scores, physical component summary (PCS) and mental component summary (MCS). The score range for each of these 2 summary scores was from 0 (poor health) to 100 (better health), higher scores indicated a better health-related quality of life. |
52 weeks
|
|
Time needed for non-invasive ventilatory support
Tidsramme: 52 weeks
|
Change from baseline in time duration that needed for non-invasive ventilatory support |
52 weeks
|
|
The viral load of adeno-associated virus (AAV) vector
Tidsramme: 52 weeks
|
To assess the change of AAV vector copy numbers within 52 weeks after administration. |
52 weeks
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
GAA enzymatic activity
Tidsramme: 52 weeks
|
Change from baseline in GAA enzymatic activity in muscle biopsies |
52 weeks
|
|
GAA enzymatic activity
Tidsramme: 52 weeks
|
Change from baseline in GAA enzymatic activity in blood |
52 weeks
|
|
Glycogen content in muscle
Tidsramme: 52 weeks
|
Change from baseline in glycogen content in muscle biopsies |
52 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studiestol: Guang Yang, Chinese PLA General Hospital
- Ledende efterforsker: Guang Yang, Chinese PLA General Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Metabolisme, medfødte fejl
- Genetiske sygdomme, medfødte
- Metaboliske sygdomme
- Kulhydratmetabolisme, medfødte fejl
- Lysosomale opbevaringssygdomme
- Hjernesygdomme, metaboliske, medfødte
- Hjernesygdomme, metaboliske
- Lysosomale opbevaringssygdomme, nervesystemet
- Glykogenopbevaringssygdom
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Ernæringsmæssige og metaboliske sygdomme
- Glykogenopbevaringssygdom type II
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- JLJY-GC301-LOPD-001
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .